Standout Papers

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma 2013 2026 2017 2021 1.3k
  1. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma (2014)
    Judith M. Müller, Oscar Krijgsman et al. Nature Communications
  2. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance (2015)
    Willy Hugo, Hubing Shi et al. Cell
  3. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression (2017)
    Ángel García-Díaz, Daniel Sanghoon Shin et al. Cell Reports
  4. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy (2013)
    Hubing Shi, Willy Hugo et al. Cancer Discovery

Immediate Impact

1 by Nobel laureates 20 from Science/Nature 60 standout
Sub-graph 1 of 21

Citing Papers

Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
2023 Standout
What is cancer metabolism?
2023 Standout
2 intermediate papers

Works of Willy Hugo being referenced

Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
2021
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation
2016
and 1 more

Author Peers

Author Last Decade Papers Cites
Willy Hugo 2489 2362 1412 43 4.2k
Zachary A. Cooper 2583 2544 1266 76 4.7k
Thinle Chodon 3233 3117 1355 33 5.2k
Uwe Trefzer 2804 2653 1082 76 4.4k
Lídia Robert 1974 1947 1312 26 3.7k
Clemens Krepler 2508 2254 1055 74 4.0k
Dennie T. Frederick 3756 3152 1663 75 6.1k
Mark Merchant 3017 1612 560 62 4.8k
Laura Soucek 3594 1707 837 54 4.9k
Gabriella Liszkay 2761 2816 765 81 3.9k
Kimberly B. Dahlman 2287 1681 448 38 3.1k

All Works

Loading papers...

Rankless by CCL
2026